Natural progression of neurological disease in mucopolysaccharidosis type II

Pediatrics

Volumn 127, Issue 5, 2011, Pages

  Holt, Joshua B ^a   Poe, Michele D ^b   Escolar, Maria L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

CNS disease; Hunter syndrome; Intrathecal therapy; Lysosomal storage disease; Mucopolysaccharidosis

Indexed keywords

ADAPTATION; ADOLESCENT; ADULT; ARTICLE; AUDIOLOGIST; CHILD; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUNTER SYNDROME; INFANT; LANGUAGE DISABILITY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MEDICAL SPECIALIST; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; OCCUPATIONAL THERAPIST; PEDIATRICIAN; PHYSIOTHERAPIST; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOLOGIST; PSYCHOMETRY; QUESTIONNAIRE; RETROSPECTIVE STUDY; SCHOOL CHILD; SPEECH DISORDER;

CHILD; CHILD, PRESCHOOL; COGNITION DISORDERS; COHORT STUDIES; DEVELOPMENTAL DISABILITIES; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; MALE; MENTAL DISORDERS; MOTOR SKILLS DISORDERS; MUCOPOLYSACCHARIDOSIS II; NERVOUS SYSTEM DISEASES; PSYCHOMETRICS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 79955493662     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-1274     Document Type: Article

References (62)

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, ed.The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001:3421-3452
2. Lowry RB, Applegarth DA, Toone JR, et al. An update on the frequency of mucopolysaccharide syndromes in British Columbia. Hum Genet. 1990;85(3):389-390 (Pubitemid 20279573)
3. Young ID, Harper PS. Incidence of Hunter's syndrome. Hum Genet. 1982;60(4):391-392 (Pubitemid 12096404)
4. Schaap T, Bach G. Incidence of mucopolysaccharidoses in Israel: is Hunter disease a "Jewish disease"? Hum Genet. 1980;56(2): 221-223
5. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249-254 (Pubitemid 29058114)
6. Baehner F, Schmiedeskamp C, Krummenauer F, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis. 2005;28(6):1011-1017 (Pubitemid 43168938)
7. Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in the Netherlands. Hum Genet. 1999; 105(1-2):151-156 (Pubitemid 29396979)
8. Mossman J, Blunt S, Stephens R, Jones EE, Pembrey M. Hunter's disease in a girl: association with X:5 chromosomal translocation disrupting the Hunter gene. Arch Dis Child. 1983;58(11):911-915 (Pubitemid 14240961)
9. Clarke JT, Willard HF, Teshima I, Chang PL, Skomorowski MA. Hunter disease (mucopolysaccharidosis type II) in a karyotypically normal girl. Clin Genet. 1990;37(5): 355-362 (Pubitemid 20161654)
10. Sukegawa K, Song XQ, Masuno M, et al. Hunter disease in a girl caused by R468Q mutation in the iduronate-2-sulfatase gene and skewed inactivation of the X chromosome carrying the normal allele. Hum Mutat. 1997;10(5):361-367 (Pubitemid 27473296)
11. Winchester B, Hurst J, Young E, et al. Female twin with Hunter disease due to nonrandom inactivation of the X-chromosome: a consequence of twinning. Am J Med Genet. 1992; 44(6):834-838 (Pubitemid 23006121)
12. Young ID, Harper PS. The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Dev Med Child Neurol. 1983;25(4):481-489 (Pubitemid 13030892)
13. Clarke LA. Idursulfase for the treatment of mucopolysaccharidosis II. Expert Opin Pharmacother. 2008;9(2);311-317
14. Lichtenstein JR, Bilbrey GL, McKusick VA. Clinical and probable genetic heterogeneity within mucopolysaccharidosis, II: report of a family with a mild form. Johns Hopkins Med J. 1972;131(6):425-435
15. Young ID, Harper PS, Newcombe RG, Archer IM. A clinical and genetic study of Hunter's syndrome: 2 differences between the mild and severe forms. J Med Genet. 1982;19(6): 408-411 (Pubitemid 13167537)
16. Martin R, Beck M, Eng C, et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics. 2008;121(2). Available at: www.pediatrics.org/cgi/content/full/121/2/e377
17. Filocamo M, Bonuccelli G, Corsolini F, Mazzotti R, Cusano R, Gatti R. Molecular analysis of 40 Italian patients with mucopolysaccharidosis type II: new mutations in the iduronate-2-sulfatase (IDS) gene. Hum Mutat. 2001;18(2);164-5
18. Bunge S, Steglich C, Beck M, et al. Mutation analysis of the iduronate-2-sulfatase gene in patients with mucopolysaccharidosis type II (Hunter syndrome). Hum Mol Genet. 1992;1(5):335-339
19. Bondeson ML, Dahl N, Malmgren H, et al. Inversion of the IDS gene resulting from recombination with IDS-related sequences is a common cause of the Hunter syndrome. Hum Mol Genet. 1995;4(4):615-621
20. Froissart R, Moreira da Silva I, Guffon N, Bozon D, Maire I. Mucopolysaccharidosis type II: genotype/phenotype aspects. Acta Paediatr Suppl. 2002;91(439):82-87
21. Gort L, Chabas A, Coll MJ. Hunter disease in the Spanish population: molecular analysis in 31 families. J Inherit Metab Dis. 1998; 21(6):655-661 (Pubitemid 28427204)
22. Li P, Bellows AB, Thompson JN. Molecular basis of iduronate- 2-sulphatase gene mutations in patients with mucopolysaccharidosis type II (Hunter syndrome). J Med Genet. 1999;36(1):21-27 (Pubitemid 29103459)
23. Vafiadaki E, Cooper A, Heptinstall LE, Hatton CE, Thornley M, Wraith JE. Mutation analysis in 57 unrelated patients with MPS II (Hunter's disease). Arch Dis Child. 1998;79(3): 237-241 (Pubitemid 28420513)
24. Timms KM, Bondeson ML, Ansari-Lari MA, et al. Molecular and phenotypic variation in patients with severe Hunter syndrome. Hum Mol Genet. 1997;6(3):479-486 (Pubitemid 27116470)
25. Parkinson EJ, Muller V, Hopwood JJ, Brooks DA. Iduronate- 2-sulphatase protein detection in plasma from mucopolysaccharidosis type II patients. Mol Genet Metab. 2004; 81(1):58-64 (Pubitemid 38064433)
26. Bergstrom SK, Quinn JJ, Greenstein R, Ascensao J. Longterm follow-up of a patient transplanted for Hunter's disease type IIB: a case report and literature review. Bone Marrow Transplant. 1994;14(4):653-658 (Pubitemid 24338498)
27. Muenzer J, Neufeld EF, Constantopoulos G, et al. Attempted enzyme replacement using human amnion membrane implantations in mucopolysaccharidoses. J Inherit Metab Dis. 1992;15(1):25-37
28. Dean MF, Stevens RL, Muir H, et al. Enzyme replacement therapy by fibroblast transplantation: long-term biochemical study in three cases of Hunter's syndrome. J Clin Invest. 1979;63(1):138-146 (Pubitemid 9085090)
29. Knudson AG Jr, Di Ferrante N, Curtis JE. Effect of leukocyte transfusion in a child with type II mucopolysaccharidosis. Proc Natl Acad Sci USA. 1971;68(8):1738-1741
30. Yatziv S, Statter M, Abeliuk P, Meshulam M, Russel A. A therapeutic trial of fresh plasma infusions over a period of 22 months in two siblings with Hunter's syndrome. Isr J Med Sci. 1975;11(8):802-808
31. Cardone M, Polito VA, Pepe S, et al. Correction of Hunter syndrome in the MPS II mouse model by AAV2/8-mediated gene delivery. Hum Mol Genet. 2006;15(7):1225-1236
32. Tomanin R, Friso A, Alba S, et al. Nonviral transfer approaches for the gene therapy of mucopolysaccharidosis type II (Hunter syndrome). Acta Paediatr Suppl. 2002; 91(439):100-104 (Pubitemid 36174160)
33. Stroncek DF, Hubel A, Shankar RA, et al. Retroviral transduction and expansion of peripheral blood lymphocytes for the treatment of mucopolysaccharidosis type II, Hunter's syndrome. Transfusion. 1999; 39(4):343-350 (Pubitemid 29181676)
34. Friso A, Tomanin R, Alba S, et al. Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts. J Gene Med. 2005;7(11): 1482-1491 (Pubitemid 41672407)
35. Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab. 2007;90(3): 325-355
36. Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) [published correction appears in Genet Med. 2006;8(9): 599]. Genet Med. 2006;8(8):465-473
37. Dickson PI. Novel treatments and future perspectives: outcomes of intrathecal drug delivery. Int J Clin Pharmacol Ther. 2009; 47(suppl 1):S124-S127
38. Kakkis E, McEntee M, Vogler C, et al. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab. 2004;83(1-2):163-174 (Pubitemid 39328075)
39. Staba S, Escolar M, Poe M, et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med. 2004;350(19):1960-1969 (Pubitemid 38580199)
40. Escolar M, Poe M, Provenzale J, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med. 2005;352(20):2069-2081 (Pubitemid 40664308)
41. Beam D, Poe M, Provenzale J, et al. Outcomes of unrelated umbilical cord blood transplantation for X-linked adrenoleukodystrophy. Biol Blood Marrow Transplant. 2007;13(6):665-674 (Pubitemid 46767994)
42. Mullen E. The Mullen Scales of Early Learning. Circle Pines, MN: American Guidance Service; 1995
43. Elliot C. The Differential Ability Scale (DAS). San Antonio, TX: Psychological Corporation; 1979
44. Roid G, Miller L. Leiter International Performance Scale, Revised Manual. Wood Dale, IL: Stoelting Company; 1997
45. Bruininks R, Woodcock R, Weatherman R. Scales of Independent Behavior, Revised: Comprehensive Manual. Chicago, IL: Riverside Publishing Company; 1996
46. Hayley S, Coster W, Ludlow L, Haltiwanger J, Andrellos P. Pediatric Evaluation of Disability Inventory (PEDI). Boston, MA: New England Medical Center Hospitals and PEDI Research Group; 1992
47. Zimmerman I, Steiner V, Pond R. Preschool Language Scale. 4th ed. San Antonio, TX: Psychological Corporation; 2002
48. Bzoch K, League R, Brown V. Receptive- Expressive Emergent Language. 3rd ed. Austin, TX: Pro-Ed; 2003
49. Semel E, Wiig E, Secord W. Clinical evaluation of language fundamentals. 4th ed. San Antonio, TX: Psychological Corporation; 2003
50. Folio M, Fewell R. Peabody Developmental Motor Scales. 2nd ed. Austin, TX: Pro-Ed; 2000
51. Martin HR, Poe MD, Reinhartsen D, et al. Methods for assessing neurodevelopment in lysosomal storage diseases and related disorders: a multidisciplinary perspective. Acta Paediatrica. 2008;97(457):69-75 (Pubitemid 351421294)
52. Thompson DC, McPhillips H, Davis R, et al. Universal newborn hearing screening: summary of evidence. JAMA. 2001;286(16): 2000-2010 (Pubitemid 33010219)
53. Wessex University Neonatal Hearing Screening Trial Group. Controlled trial of universal neonatal screening for early identification of permanent childhood hearing impairment. Lancet. 1998;352(9145):1957-1964
54. Parker S, Zuckerman B. Behavioral and Developmental Pediatrics: A Handbook for Primary Care. 2nd ed. Boston, MA: Little, Brown and Company; 2005
55. Finn CT, Vedolin L, Schwartz IV, et al. Magnetic resonance imaging findings in Hunter syndrome. Acta Paediatr. 2008;97(457): 61-68 (Pubitemid 351421289)
56. Pinto L, Schwartz I, Puga A, Vieira T, Munoz M, Giugliani R. Prospective study of 11 Brazilian patients with mucopolysaccharidosis II. J Pediatr (Rio J). 2006;82(4): 273-278
57. Gelb M, Turecek F, Scott R, Chamoles N. Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis. 2006;29(2-3):397-404 (Pubitemid 43880641)
58. Wang D, Wood T, Sadilek M, Scott CR, Turecek F, Gelb M. Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: Application to newborn screening for mucopolysaccharidosis II (Hunter disease). Clin Chem. 2007;53(1):137-140 (Pubitemid 46047775)
59. Chamoles N, Blanco M, Gaggioli D, Casentini C. Hurler-like phenotype: enzymatic diagnosis in dried blood spots on filter paper. Clin Chem. 2001;47(12):2098-2102 (Pubitemid 33108873)
60. Meikle P, Ranieri E, Simonsen H, et al. Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy. Pediatrics. 2004;114(4): 909-916 (Pubitemid 41529752)
61. Millington DS, Sista R, Eckhardt A, et al. Digital microfluidics: a future technology in the newborn screening laboratory? Semin Perinatol. 2010;34(2):163-169
62. Kato T, Kato Z, Kuratsubo I, et al. Evaluation of ADL in patients with Hunter disease using FIM score. Brain Dev. 2007;29(5):298-305 (Pubitemid 46483915)